US23255M2044 - Common Stock
CYCLERION THERAPEUTICS INC
NASDAQ:CYCN (12/18/2024, 3:50:43 PM)
2.85
-0.43 (-13.11%)
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The firm operates through the human therapeutics segment. The firm is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The firm is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142
P: 16176217722
CEO: Peter M. Hecht
Employees: 1
Website: https://www.cyclerion.com/
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat
Cyclerion is leveraging its legacy sGC stimulator assets to generate near-term revenues which will be used to implement its strategic building plan....
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Which stocks are gapping on Thursday?
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Here you can normally see the latest stock twits on CYCN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: